ACT logo

AlzChem Group AG Stock Price

XTRA:ACT Community·€1.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 45 Fair Values set on narratives written by author

ACT Share Price Performance

€146.40
95.40 (187.06%)
20.9% undervalued intrinsic discount
€185.00
Fair Value
€146.40
95.40 (187.06%)
20.9% undervalued intrinsic discount
€185.00
Fair Value
Price €146.40
AnalystHighTarget €185.00
AnalystConsensusTarget €154.24
AnalystLowTarget €97.00

ACT Community Narratives

AnalystHighTarget·
Fair Value €185 20.9% undervalued intrinsic discount

Rising Global Protein Demand Will Fuel Sustainable Specialty Chemicals

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystConsensusTarget·
Fair Value €154.24 5.1% undervalued intrinsic discount

Global Nutrition Trends And Capacity Expansions Will Unlock Opportunities

2users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AnalystLowTarget·
Fair Value €97 50.9% overvalued intrinsic discount

Rising Environmental Mandates And Input Costs Will Squeeze Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent ACT News & Updates

Is AlzChem Group (ETR:ACT) Using Too Much Debt?

Sep 13
Is AlzChem Group (ETR:ACT) Using Too Much Debt?

Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?

Aug 20
Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?

AlzChem Group AG Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 02
AlzChem Group AG Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

AlzChem Group AG (ETR:ACT) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 22
AlzChem Group AG (ETR:ACT) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Returns Are Gaining Momentum At AlzChem Group (ETR:ACT)

Jun 02
Returns Are Gaining Momentum At AlzChem Group (ETR:ACT)

A Look At The Fair Value Of AlzChem Group AG (ETR:ACT)

May 19
A Look At The Fair Value Of AlzChem Group AG (ETR:ACT)

AlzChem Group AG Key Details

€566.3m

Revenue

€207.7m

Cost of Revenue

€358.5m

Gross Profit

€300.6m

Other Expenses

€57.9m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 30, 2025
Earnings per share (EPS)
5.71
Gross Margin
63.32%
Net Profit Margin
10.23%
Debt/Equity Ratio
20.2%

AlzChem Group AG Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Outstanding track record with flawless balance sheet.

0 Risks
3 Rewards

About ACT

Founded
1908
Employees
1647
CEO
Andreas Niedermaier
WebsiteView website
www.alzchem.com

AlzChem Group AG, together with its subsidiaries, develops, produces, and markets a range of chemical specialties in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The Specialty Chemicals segment sells specialty chemical products that are used in the chemical, food, animal feed, defence technology, and renewable energies industries. This segment manufactures composite materials and adhesives, as well as silicon nitride for ceramics; and photovoltaic modules in the solar industry. The Basics & Intermediates segment produces raw materials for specialty chemicals; and products for agriculture and metallurgy, as well as intermediates for the chemical industry that are produced from lime, carbon, and electricity. This segment also engages in the production and sale of guanidine salts as a raw material for agrochemicals and active pharmaceutical ingredients. The Other & Holding segment provides chemical park operations and administrative services, as well as produces and distributes various infrastructure services. It offers products and services to agricultural sector under the CALCIUM CYANAMIDE PERLKA, EMINEX, DORMEX, ALZOGUR, SITOFEX, and BREAK-THRU brands; animal nutrition sector under the CREAMINO brands; human nutrition sector under the CREAPURE, CREAVITALIS, LIVADUR, and ALIPURE brands; pharma sector under the GUANIDINE SALTS – BIOSELECT brand; fine chemicals sector under the GUANIDINSALZE -BIOSELECT, CYANAMIDE, DICYANDIAMIDE, GUANAMINE, NITRILES, MELFLOCK and ALZOFIX, THIOUREA, and NITROGUANIDINE brands; metallurgy sector under the CAD, CALCIPRO, and CALZOT brands, as well as technical gases and calcium carbide; renewable energy sector under the DYHARD and SILZOT brands; and custom synthesis, such as toll micronization and manufacturing. The company was founded in 1908 and is based in Trostberg, Germany.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

German Market Performance

  • 7 Days: 2.7%
  • 3 Months: -0.3%
  • 1 Year: 14.9%
  • Year to Date: 13.4%
The market is up 2.6% in the last 7 days, led by the Industrials and all sectors gaining ground. As for the past 12 months, the market is up 15%. As for the next few years, earnings are expected to grow by 17% per annum. Market details ›